George Golumbeski - Acceleron Pharma Independent Director
Director
Dr. George S. Golumbeski, Ph.D., is no longer Independent Director of the Company effective June 6, 2018. He joined Celgene in early 2009, is Executive Vice President of Business Development, where he is responsible for the full array of business development activities, including identification and evaluation of opportunities, structuring and negotiating transactions, inlicensing, MA, outlicensing, and alliance management. At Celgene, these activities are focused primarily within the therapeutic areas of oncology and inflammation. Since 2014, Dr. Golumbeski has served on the board of directors of one other public company, Enanta Pharmaceuticals, Inc., and has served as a trustee of the Keck Graduate Institute since 2013. Dr. Golumbeski has also served as a member of the board of directors of the National Audubon Society since 2015. From 2008 to 2009, Dr. Golumbeski served as the CEO of Nabriva Therapeutics AG. Prior to Nabriva, Dr. Golumbeski served as Vice President of Business Development, Licensing and Strategy for NovartisOncology. During his tenure at Novartis, Dr. Golumbeski group closed a significant number of collaboration agreements which bolstered the development pipeline. Earlier in his career, Dr. Golumbeski held senior positions at Elan Pharmaceuticals and at Schwarz Pharma, where he led the effort to inlicense rotigotine and lacosamide since 2011.
| Age | 59 |
| Tenure | 13 years |
| Professional Marks | Ph.D |
| Phone | 617 649-9200 |
| Web | www.acceleronpharma.com |
Acceleron Pharma Management Efficiency
The company has return on total asset (ROA) of (16.73) % which means that it has lost $16.73 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (29.16) %, meaning that it created substantial loss on money invested by shareholders. Acceleron Pharma's management efficiency ratios could be used to measure how well Acceleron Pharma manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 22.43 M in liabilities with Debt to Equity (D/E) ratio of 0.03, which may suggest the company is not taking enough advantage from borrowing. Acceleron Pharma has a current ratio of 14.51, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Acceleron Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Acceleron Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Acceleron Pharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Acceleron to invest in growth at high rates of return. When we think about Acceleron Pharma's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Jeffrey Wright | Hawkins | 54 | |
| Norman Edelcup | Valhi Inc | 78 | |
| Joachim Faber | Coty Inc | 67 | |
| Kenneth Manning | Sealed Air | 73 | |
| Henry Keizer | Sealed Air | 63 | |
| Patrick Duff | Sealed Air | 59 | |
| David Seaton | The Mosaic | 59 | |
| Oscar Bernardes | The Mosaic | 73 | |
| Harry Lawton | Sealed Air | 45 | |
| Denise Johnson | The Mosaic | 53 | |
| Elisabeth Fisher | Valhi Inc | 59 | |
| Thomas Barry | Valhi Inc | 76 | |
| Anna Makanju | Coty Inc | 44 | |
| Paul Michaels | Coty Inc | 64 | |
| Francoise Colpron | Sealed Air | 48 | |
| Hayden McIlroy | Valhi Inc | 78 | |
| Bobby OBrien | Valhi Inc | 58 | |
| James Faulconbridge | Hawkins | 49 | |
| Mary Schumacher | Hawkins | 60 | |
| Emery Koenig | The Mosaic | 64 | |
| Luciano Pires | The Mosaic | 50 | |
Management Performance
| Return On Equity | -29.16 | |||
| Return On Asset | -16.73 |
Acceleron Pharma Leadership Team
Elected by the shareholders, the Acceleron Pharma's board of directors comprises two types of representatives: Acceleron Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Acceleron. The board's role is to monitor Acceleron Pharma's management team and ensure that shareholders' interests are well served. Acceleron Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Acceleron Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jean George, Independent Director | ||
| Terrance McGuire, Independent Director | ||
| Matthew Sherman, Senior Vice President Chief Medical Officer | ||
| Robert Zeldin, Chief Medical Officer | ||
| Christopher Rovaldi, Senior Vice President Program Management and Operations | ||
| Richard Pops, Independent Director | ||
| Ravindra Kumar, Chief Scientific Officer, Vice President | ||
| Thomas McCourt, Director | ||
| Francois Nader, Director | ||
| John Quisel, Vice President General Counsel, Secretary | ||
| Tom Maniatis, Independent Director | ||
| John Knopf, Founder, CEO and President and Director | ||
| Steven Ertel, COO and Executive VP | ||
| George Golumbeski, Independent Director | ||
| Terrence Kearney, Director | ||
| Karen Smith, Director | ||
| Todd James, IR Contact Officer | ||
| Sujay Kango, Chief Commercial Officer | ||
| Kevin McLaughlin, CFO, Sr. VP and Treasurer | ||
| Joseph Zakrzewski, Independent Director | ||
| Habib Dable, President CEO, Director |
Acceleron Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Acceleron Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -29.16 | |||
| Return On Asset | -16.73 | |||
| Profit Margin | (158.11) % | |||
| Operating Margin | (158.79) % | |||
| Current Valuation | 6.93 B | |||
| Shares Outstanding | 60.7 M | |||
| Shares Owned By Insiders | 11.86 % | |||
| Shares Owned By Institutions | 90.60 % | |||
| Number Of Shares Shorted | 2.12 M | |||
| Price To Earning | (14.74) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Current Watchlist to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Other Consideration for investing in Acceleron Stock
If you are still planning to invest in Acceleron Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Acceleron Pharma's history and understand the potential risks before investing.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |